Edesa Biotech, Inc. (NASDAQ:EDSA)
| Market Cap | $18.69M+10.9% |
| Revenue (ttm) | $0 |
| Net Income | -$14.10M-138.2% |
| EPS | -$1.69-27.1% |
| Shares Out | 9.63M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 507,554 |
| Open | $1.96 |
| Previous Close | $2.08 |
| Day's Range | $1.78 - $1.96 |
| 52-Week Range | $0.72 - $20.32 |
| Beta | 1.06 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Dec 11, 2026 |
About EDSA
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Dec 11, 2026Earnings report
$EDSA stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in EDSA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by EDSA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
EDSA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New EDSA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to EDSA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in EDSA
| VXFVanguard Extended Market ETF | $344.54K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from EDSA’s recent data — informational, not investment advice
What’s Behind the Score
News check: Major licensing deal with Kyorin worth up to $146M for Paridiprubart provides significant revenue potential and validates product viability.